+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Effect of tripterygium glycosides on serum interleukin-1beta, interleukin-2, tumor necrosis factor alpha, and interferon-gamma levels in patients with Behcet's disease

Effect of tripterygium glycosides on serum interleukin-1beta, interleukin-2, tumor necrosis factor alpha, and interferon-gamma levels in patients with Behcet's disease

Zhongguo Zhong Xi Yi Jie he Za Zhi Zhongguo Zhongxiyi Jiehe Zazhi 30(6): 598-600

To investigate the possible mechanism of action of tripterygium glycosides (TG) for treatment of Behcet's disease (BD) through observing its effect on serum levels of interleukin-1beta (IL-1beta), interleukin-2 (IL-2), tumor necrosis factor alpha (TNF-alpha) and interferon-gamma (IFN-gamma). Thirty primarily treated BD patients (BD group) were treated with TG 30 mg/d orally for 3 months, and a control group consisting of 30 healthy persons was set up. Serum levels of IL-1beta, IL-2, TNF-alpha and IFN-gamma were detected by radio-immunosorbent assay (RIA) before and after treatment respectively. And the outcomes were analyzed in combining with the clinical status of patients as well as related indices as erythrocyte sedimentation (ESR) and C-reactive protein (CRP). Serum levels of IL-1beta, TNF-alpha, IFN-gamma in the BD group were evidently higher (P < 0.05) than those in the control group, they all lowered significantly after 3-month TG treatment, from 10.72 +/- 1.84 microg/L, 6.64 +/- 1.05 microg/L and 8.93 +/- 1.23 microg/L to 5.71 +/- 1.04 microg/L, 4.27 +/- 0.76 microg/L and 3.44 +/- 0.72 microg/L, respectively (P < 0.05), while level of IL-2 in the BD group was insignificantly different before treatment to that in the control (though showed an increasing trend) and was unchanged after treatment (P > 0.05). TG treatment showed the effectiveness of markedly effective in 10, effective in 16 and ineffective in 4 BD patients, with the total effective rate of 86.6%. Besides, ESR and CRP levels were evidently decreased in BD patients after treatment (P < 0.05). TG may treat BD by way of regulating the levels of IL-1beta,TNF-alpha and IFN-gamma.

Please choose payment method:

(PDF emailed within 1 workday: $29.90)

Accession: 052835339

Download citation: RISBibTeXText

PMID: 20815274

Related references

Effects of interferon-alpha2a treatment on serum levels of tumor necrosis factor-alpha, tumor necrosis factor-alpha2 receptor, interleukin-2, interleukin-2 receptor, and E-selectin in Behçet's disease. Rheumatology International 19(1-2): 11-14, 1999

Modulation of interleukin-1beta, interleukin-4, interleukin-6 interleukin-10, tumor necrosis factor-alpha and interferon-gamma by aqueous extracts of Swertia chirayita. Indian Journal of Pharmacology 34(2): 141, 2002

Interleukin 1 interleukin 2 interleukin 4 interleukin 6 tumor necrosis factor alpha and interferon gamma levels in sera from patients with scleroderma. Arthritis & Rheumatism 35(1): 67-72, 1992

Serum levels of interleukin-1beta, interleukin-2 receptor, interleukin-6 and tumor necrosis factor-alpha levels in patient with chronic liver disease. Journal of Hepatology 34(Suppl. 1): 216-217, 2001

Swertia chirayita mediated modulation of interleukin-1beta, interleukin-6, interleukin-10, interferon-gamma, and tumor necrosis factor-alpha in arthritic mice. Immunopharmacology and Immunotoxicology 25(4): 573-583, 2003

Elevated serum interleukin 6, interferon-gamma, and tumor necrosis factor-alpha levels in patients with adult Still's disease. Journal of Rheumatology 25(2): 396-398, 1998

Interferon-gamma and bacterial lipopolysaccharide act synergistically on human neutrophils enhancing interleukin-8, interleukin-1beta, tumor necrosis factor-alpha, and interleukin-12 p70 secretion and phagocytosis via upregulation of toll-like receptor 4. Shock 27(3): 226-231, 2007

Longitudinal study of inflammatory factors in serum, cerebrospinal fluid, and brain tissue in Alzheimer disease: interleukin-1beta, interleukin-6, interleukin-1 receptor antagonist, tumor necrosis factor-alpha, the soluble tumor necrosis factor receptors I and II, and alpha1-antichymotrypsin. Alzheimer Disease and Associated Disorders 12(3): 215-227, 1998

Complement factor I is upregulated in rat hepatocytes by interleukin-6 but not by interferon-gamma, interleukin-1beta, or tumor necrosis factor-alpha. Biological Chemistry 382(7): 1089-1094, 2001

Complement factor I is upregulated in rat hepatocytes and HUVEC by interleukin-6 but not by interferon-gamma, interleukin-1beta or tumor necrosis factor-alpha. Molecular Immunology 38(2-3): 84-85, 2001

Serum interleukin-2, interleukin-6, tumour necrosis factor-alpha and nitric oxide levels in patients with Behcet's disease. Annals of the Academy of Medicine, Singapore 33(5): 596-599, 2004

Association of reduced tumor necrosis factor alpha, gamma interferon, and interleukin-1beta (IL-1beta) but increased IL-10 expression with improved chest radiography in patients with pulmonary tuberculosis. Clinical and Vaccine Immunology 17(2): 223-231, 2010

Serum levels of interferon-gamma, interleukin-12, tumour necrosis factor-alpha, and interleukin-10, and bacterial clearance in patients with gastroenteric Salmonella infection. Scandinavian Journal of Infectious Diseases 37(1): 11-14, 2005

Circulating levels of interleukin 1 alpha tumor necrosis factor interferon gamma and soluble interleukin 2 receptor are high in children with autoimmune chronic liver disease. Hepatology 12(4 Part 2): 937, 1990

Serum levels of proinflammatory cytokines interleukin-1beta, interleukin-6, and tumor necrosis factor alpha in mixed cryoglobulinemia. Arthritis and Rheumatism 60(12): 3841-3847, 2009